Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wet AMD

Sex eligibility

All sexes

Study type

Observational

Primary location

Retina Institute of Hawaii

Honolulu, Hawaii, 96815, United States

About this study

To determine mean change in visual acuity at 6 and 12 months

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ability to provide written informed consent and comply with study assessments for the full duration of the study
Age greater then and equal 50 years
Patients with active neovascular AMD
Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion criteria

Subjects who meet any of the following criteria will be excluded from this study:
Pregnancy or lactation
Premenopausal women not using adequate contraception.
Participation in another simultaneous medical investigation

Treatment and study plan

Lucentis

Drug

0.5mg Lucentis every four months

Primary outcomes

Mean change in visual acuity at 6 and 12 months

Time frame: one year

Sponsors and collaborators

Lead sponsor

Retina Institute of Hawaii

Other

Registry information

Official study title

Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2009
First posted: Dec 9, 2008
Registry last updated: May 28, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed